背景至关重要——结直肠癌共识分子亚型作为临床试验生物标志物
结直肠癌分型联盟基于早期结肠癌原发肿瘤样本的微阵列或RNA测序数据,确定了四种基因表达共识分子亚型:CMS1(免疫型)、CMS2(经典型)、CMS3(代谢型)和CMS4(间质型)。直肠肿瘤和IV期肿瘤代表性不足,且未纳入放化疗前样本或转移灶。临床应用该分类器时需考虑样本来源和治疗史等背景因素。
要点
- CMS分型基于早期结肠癌原发肿瘤数据,直肠癌和IV期肿瘤代表性不足。
- 未纳入放化疗前样本或转移灶,样本来源和治疗史影响基因表达和亚型分类。
- 临床试验相关性分析显示该分类可用于转移 setting,并提示不同亚型对治疗敏感性存在差异。
核心结论
- 结直肠癌分型联盟确定了四种共识分子亚型:CMS1(免疫型)、CMS2(经典型)、CMS3(代谢型)和CMS4(间质型)。
- 应用分类器到新数据集时,必须仔细考虑样本来源和患者采集前接受的治疗。
- 分析临床试验数据时需考虑背景和模棱两可的因素,包括潜在选择偏倚、平台类型和亚型预测算法类型。
研究设计与样本
- 结直肠癌分型联盟使用主要来自早期结肠癌患者的原发肿瘤样本的多个微阵列或RNA测序数据集。
主要发现
- 直肠肿瘤和IV期肿瘤(可能反映更具侵袭性的疾病)代表性不足。
- 未纳入化疗和/或放疗前处理的样本或转移灶。
- 近期多项临床试验的相关性分析证明了该分类在转移 setting 的适用性,证实了复发后CMS亚型的预后价值,并提示对治疗的差异敏感性。
关键数值与推荐
- 四种共识分子亚型:CMS1(免疫型)、CMS2(经典型)、CMS3(代谢型)和CMS4(间质型)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 直肠肿瘤和IV期肿瘤代表性不足。
- 未纳入化疗和/或放疗前处理的样本或转移灶。
- 样本来源和患者采集前接受的治疗可能影响基因表达和亚型分类。
- 分析临床试验数据时需考虑潜在选择偏倚、平台类型和亚型预测算法类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be carefully considered when applying the classifier to new datasets. Recently, several correlative analyses of clinical trials demonstrated the applicability of this classification to the metastatic setting, confirmed the prognostic value of CMS subtypes after relapse and hinted at differential sensitivity to treatments. Here, we discuss why contexts and equivocal factors need to be taken into account when analyzing clinical trial data, including potential selection biases, type of platform, and type of algorithm used for subtype prediction. This perspective article facilitates both our clinical and research understanding of the application of this classifier to expedite subtype-based clinical trials.
引用
- Fontana E, Eason K, Cervantes A, et al. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol. 2019. PMID: 30796810. doi:10.1093/annonc/mdz052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。